Incyte Corp. (INCY)
INCY trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$108.62
-2.46% on the day
Market cap
$22.0B
Large cap
Revenue · 2025
$5.1B
+21.2% on 2024
Net income · 2025
$1.3B
25.0% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | INCY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000879169 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $5.1B |
| Net income | $1.3B |
| Operating income | $1.5B |
| Net margin | 25.0% |
| Operating margin | 29.5% |
| Revenue growth | +21.2% |
| Cash | $3.1B |
| Total assets | $7.0B |
| P/E (computed) | 17.1× |
| P/S (computed) | 4.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-02-10 |
| Latest annual report | 10-K | 2026-02-10 |
| Latest quarterly / interim | 10-Q | 2026-07-28 |
| Latest current report | 8-K | 2026-08-31 |
| Latest proxy | DEFA14A | 2026-05-27 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.6% |
| 1 month | -8.3% |
| 3 months | -4.3% |
| Year to date | +13.0% |
| 1 year | +31.7% |
| From 52-week high | -14.1% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MEDP | Medpace Holdings Inc. | $609.89 | -1.64% | $17.0B |
| CRL | Charles River Laboratories International Inc. | $299.02 | -0.94% | $14.3B |
| ICLR | ICON plc | $164.34 | -0.04% | $12.6B |
| IQV | IQVIA Holdings Inc. | $260.68 | -0.58% | $42.9B |
| ABSI | Absci Corporation | $9.10 | -5.89% | $1.6B |
| OABI | OmniAb Inc. | $4.70 | -1.47% | $683.3M |
| NRC | NRC Health | $20.17 | -1.18% | $446.2M |
| MXCT | MaxCyte Inc. | $0.9643 | -3.08% | $99.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier